Confusion over whether CBD should be considered a narcotic drug has developed into a major question mark over the substance’s future in Europe.
Based on a plain reading of the 1961 Single Convention on Narcotic Drugs (1961 Convention), the European Commission (EC) considers CBD that is extracted from a cannabis plant a narcotic, and therefore its Directorate-General for Health (DG Santé) has placed a hold on novel food applications for non-synthetic CBD products until a final decision is made.
This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.
Our Key Benefits
The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.
CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.
Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Thanks for getting in touch with us
Please leave your enquiry and we will get back to you within 24 hours